The initiative aims to raise awareness of the role of virtual twins in accelerating medical research and delivering personalized care. On social media, Emma Twin will document how she, as a virtual twin, helps doctors and researchers better understand diseases and the effects of treatments, without risk to real patients.
The deal is an expansion of an existing production agreement between the companies and just one of several deals with large pharma companies that the Korean biotech has scooped up this year.
Reuters was not immediately able to authenticate the report. Novo Nordisk declined to comment on the report, but said in an emailed statement that the site was “running and producing for the market”.
Ahead of the vote at the extraordinary general meeting, Sandoz CEO Richard Saynor said the new company is eyeing the launch of at least five additional biologic drugs over the longer term.
Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland’s Novartis works to enhance its investor appeal ahead of its market debut next month.
Biopharma companies buying stock in one another did not used to be an unusual practice, but experts told BioSpace this is becoming less common due to greater market volatility.
The company will save about $130 million in 2024-25 as it eliminates 176 roles.
A U.S. federal judge said Meta Platforms must face a lawsuit claiming that it violated the medical privacy of patients who were treated by hospitals and other healthcare providers that used its Meta Pixel tracking tool.
The company is open to making big acquisitions if they make “sense”, Chief Executive Thomas Schinecker said, with the Swiss drugmaker unencumbered by its $20.7 billion deal last year to buy back its shares from Novartis.
As biosimilars and other next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance.
